Crossref
Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment
Diabetic Medicine · 31.10.2026
DOI: 10.1111/dme.70524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 31.10.2026. Verfasst von Hong Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Emergency General Hospital, Beijing, China. Die Arbeit nennt 5 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
cardiovascular riskliraglutidetype 1 diabetes
Autor:innen und Institutionen
- Department of Emergency, Emergency General Hospital, Beijing, China.
ORCID-Profile: Guobin Miao
Zitieren
APA
Zhou, H., & Miao, G. (2026). Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment. Diabetic Medicine. https://doi.org/10.1111/dme.70524
Vancouver
Zhou H, Miao G. Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment. Diabetic Medicine. 2026. doi:10.1111/dme.70524
BibTeX
@article{Zhou2026,
author = {Zhou, Hong and Miao, Guobin},
title = {Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70524}
}
EUVIMED